Biocryst Pharmaceuticals (BCRX) Net Income towards Common Stockholders (QoQ) (2010 - 2026)
Powered by 
Analysis
Biocryst Pharmaceuticals (BCRX) Net Income towards Common Stockholders (QoQ) (2010 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 212.04 Bn | 198.05 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 181.35 Bn | 178.17 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.22 Bn | 124.37 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.94 Bn | 74.94 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.53 Bn | 56.34 Bn | 1.37 Bn |
| 6 | Moderna | 54.25 Bn | 49.11 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.41 Bn | 31.10 Bn | 992.69 Mn |
| 8 | Biogen | 31.19 Bn | 29.91 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.10 Bn | 30.10 Bn | 1.16 Mn |
| 10 | Biocryst Pharmaceuticals | 2.31 Bn | 1.95 Bn | 214.41 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 110.86% |
| Mar 31, 2026 | -393.60% |
| Dec 31, 2025 | 1,805.92% |
| Sep 30, 2025 | 153.67% |
| Jun 30, 2025 | 15,790.63% |
| Mar 31, 2025 | 100.12% |
| Dec 31, 2024 | -90.94% |
| Sep 30, 2024 | -10.72% |
| Jun 30, 2024 | 64.18% |
| Mar 31, 2024 | 42.69% |
| Dec 31, 2023 | -70.77% |
| Sep 30, 2023 | 52.01% |
| Jun 30, 2023 | -41.24% |
| Mar 31, 2023 | 25.45% |
| Dec 31, 2022 | -68.25% |
| Sep 30, 2022 | 27.76% |
| Jun 30, 2022 | 20.67% |
| Mar 31, 2022 | -317.32% |
| Dec 31, 2021 | 69.76% |
| Sep 30, 2021 | -36.12% |